Live Breaking News & Updates on Aurinia Lupkynis|Page 3

Stay updated with breaking news from Aurinia lupkynis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS® (Voclosporin) For Adults with Active Lupus Nephritis

Aurinia Pharmaceuticals Inc. today announced that the National Institute for Health and Care Excellence has recommended LUPKYNIS® as an option for treating adults with active lupus nephritis . | May 3, 2023 ....

United States , United Kingdom , Great Britain , Peter Greenleaf , Healthcare Products Regulatory Agency , Aurinia Pharmaceuticals Inc , National Institute For Health , Aurinia Pharmaceuticals , National Institute , Care Excellence , Chief Executive Officer , European Commission Approved , Red Cell Aplasia , Drug Interactions , Moderate Hepatic Impairment , Prescribing Information , Boxed Warning , Medication Guide , Renal Response , Active Lupus With Voclosporin , Renal Assessments , Aurinia Renal Response , Lupus With Voclosporin , Aurinia Pharmaceuticals Inc Stock Exchange , Press Release , Ephritis Auph Ca05156v1022 ,

Aurinia Pharmaceuticals Inc.: Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS (Voclosporin) For Adults with Active Lupus Nephritis

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the National Institute for Health and Care Excellence (NICE) has recommended LUPKYNIS (voclosporin) as an option ....

United States , United Kingdom , Great Britain , Peter Greenleaf , Aurinia Pharmaceuticals , National Institute For Health , Aurinia Pharmaceuticals Inc , Healthcare Products Regulatory Agency , National Institute , Care Excellence , Chief Executive Officer , European Commission Approved , Red Cell Aplasia , Drug Interactions , Moderate Hepatic Impairment , Prescribing Information , Boxed Warning , Medication Guide , Renal Response , Active Lupus With Voclosporin , Renal Assessments , Aurinia Renal Response , Lupus With Voclosporin ,

Aurinia Pharmaceuticals Announces Swissmedic Approval of LUPKYNIS® (voclosporin)

Aurinia Pharmaceuticals Inc. today announced that the Swiss Agency for Therapeutic Products has granted marketing authorization of LUPKYNIS® in combination with a background immunosuppressive. | May 2, 2023 ....

United Kingdom , United States , Peter Greenleaf , Aurinia Pharmaceuticals , Swiss Agency For Therapeutic Products Swissmedic , European Union , Aurinia Pharmaceuticals Inc , Otsuka Pharmaceutical Co Ltd , Swiss Agency , Therapeutic Products , Orphan Drug , Chief Executive Officer , Red Cell Aplasia , Drug Interactions , Moderate Hepatic Impairment , Prescribing Information , Boxed Warning , Medication Guide , Aurinia Pharmaceuticals Inc Stock Exchange , Press Release , Ackground Auph Ca05156v1022 ,

Toni Braxton Reveals She Had Emergency Heart Surgery

The Grammy-winning singer reveals the details of her ‘traumatic moment’ and how its changed her life. ....

Toni Braxton , Braxton Family Values , Get Uncomfortable , Systemic Lupus Erythematosus , Un Break My Heart , Traci Braxton , Braxton Family Values , He Root ,

Aurinia Pharmaceuticals Announces New and Refined Method of Use Patent for LUPKYNIS in the Treatment of Lupus Nephritis Issued by United States Patent and Trademark Office

EDMONTON - Aurinia Pharmaceuticals Inc. today announced that the United States Patent and Trademark Office has issued a new and refined method of use patent titled IMPROVED PROTOCOL FOR TREATMENT. | April 12, 2023 ....

United States , Aurinia Pharmaceuticals Inc , Aurinia Pharmaceuticals , Trademark Office , United States Patent , Orange Book , News Publishing , Aurinia Pharmaceuticals Inc Stock Exchange , Press Release , Or Auph Ca05156v1022 ,